The House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China’s Gan & Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs.
For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.
Minnesota’s attorney general filed a lawsuit accusing Sanofi, Novo Nordisk and Eli Lilly of deceptively raising prices for insulin.
Copenhagen, Denmark-based Novo Nordisk acquired Bristol, UK-based Ziylo in a deal that could exceed $800 million.
Pregnant women who have both severe obesity and diabetes may be more likely to have children with autism, ADHD and other psychiatric disorders than mothers who do not have either condition during pregnancy, a new study suggests.
Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogs may be effective treatments for Parkinson’s disease.
The U.S. Food and Drug Administration approved Sanofi’s Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market.
After nearly a century building a company worth $125 billion based on injectable drugs, Denmark’s Novo Nordisk – the world’s biggest insulin maker – wants to prove during 2018 that it can transform the diabetes market with a pill.